Fayez Sarofim & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Fayez Sarofim & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-6,150	Closed	-$204K	–	246
2017 Q2	$204K	Buy	+6,150	New	+$190K	﹤0.01%	238
2017 Q1	–	Sell	-6,150	Closed	-$223K	–	248
2016 Q4	$223K	Hold	6,150	–	–	﹤0.01%	233
2016 Q3	$283K	Hold	6,150	–	–	﹤0.01%	223
2016 Q2	$309K	Hold	6,150	–	–	﹤0.01%	214
2016 Q1	$329K	Hold	6,150	–	–	﹤0.01%	207
2015 Q4	$404K	Hold	6,150	–	–	﹤0.01%	191
2015 Q3	$347K	Hold	6,150	–	–	﹤0.01%	202
2015 Q2	$363K	Hold	6,150	–	–	﹤0.01%	202
2015 Q1	$383K	Hold	6,150	–	–	﹤0.01%	196
2014 Q4	$354K	Hold	6,150	–	–	﹤0.01%	199
2014 Q3	$331K	Hold	6,150	–	–	﹤0.01%	209
2014 Q2	$322K	Hold	6,150	–	–	﹤0.01%	220
2014 Q1	$325K	Sell	6,150 -150	-2%	-$6.93K	﹤0.01%	209
2013 Q4	$253K	Buy	+6,300	New	+$248K	﹤0.01%	228
2013 Q2	$241K	Buy	+6,150	New	+$240K	﹤0.01%	214

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fayez Sarofim & Co's TEVA Position: Q3 2017 in Review

Fayez Sarofim & Co sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 6,150 shares — an estimated $204K sold.

Fayez Sarofim & Co first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $404K in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Fayez Sarofim & Co reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Fayez Sarofim & Co sold 6,150 Teva Pharmaceuticals shares in Q3 2017, an estimated $204K.
Fayez Sarofim & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Fayez Sarofim & Co's Teva Pharmaceuticals position peaked at $404K in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Fayez Sarofim & Co's 13F filing for Q3 2017, filed 8 Nov 2017.